New England Journal of Medicine· 2020Q1
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- 2,701citations
- Q1SCImago
- 2020year
Short summary
In patients with type 2 diabetes and chronic kidney disease (CKD), finerenone significantly reduced the risk of kidney failure, sustained eGFR decrease, or death from renal causes by 17.8% compared to placebo over a median 2.6-year follow-up (HR 0.82, P=0.001). Cardiovascular events were also reduced.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Endocrinology, Diabetes and Metabolism
Endocrinology, Diabetes and MetabolismMedicine